Oncocin
A designed antimicrobial peptide, built from insect peptides, that kills Gram-negative bacteria by jamming their ribosome rather than bursting them. A research compound, not a drug
Oncocin is not a natural peptide but a designed one: an optimized proline- and arginine-rich antimicrobial peptide (a PrAMP) engineered around 2010 from insect defence peptides to be a cleaner antibacterial lead. Its best-known form, Onc112, is nineteen amino acids long. Like the natural PrAMPs apidaecin and drosocin, oncocin is non-lytic: rather than breaking bacterial membranes it is imported into the cell through a bacterial transporter and then binds inside the ribosome — the protein-making machine — blocking protein synthesis. Because it works by uptake into an internal target, oncocin is mainly active against Gram-negative bacteria and is gentle on host cells, with very low toxicity and little or no destruction of red blood cells. Oncocin is one of the most thoroughly characterized PrAMP antibiotic leads, with a known ribosome-bound structure and a large library of engineered analogs made to improve its potency and stability. Oncocin is a research peptide; it is not an approved medicine and has not been given to people as a treatment.
No established human dose Details ↓
Recommended Dosing
No established human dose
Oncocin is a designed research peptide; it has not been given to people as a treatment. The work is in bacteria and cell-free systems, almost always with synthetic analogs, at experimental amounts that do not carry over to people.
Work out syringe units → · New to syringes? · All dosing data ↓ · Dose and vial tracker · Is this vial OK?
What is it?
Many antimicrobial peptides are optimized versions of natural ones, and oncocin is a prime example. Starting from insect proline-rich antimicrobial peptides — the family that includes the milkweed bug's oncopeltus factor and the related pyrrhocoricin — researchers around 2010 designed a cleaner, more potent analog, oncocin, whose lead form Onc112 has the nineteen-residue sequence VDKPPYLPRPRPPRRIYNR. Rich in proline and arginine and carrying no disulfide bonds, oncocin belongs to the same non-lytic class as the honeybee's apidaecin and the fruit fly's drosocin.
Its mechanism is well mapped. Oncocin's action has three stages: it diffuses across the Gram-negative outer membrane, is actively pumped across the inner membrane by a bacterial transporter (SbmA), and then binds inside the ribosome's nascent-peptide exit tunnel to block protein synthesis — early biochemistry also identified the chaperone DnaK as a target. Because it targets an internal machine rather than the membrane, oncocin is gentle on host cells: engineered analogs routinely show less than one percent hemolysis even at very high concentrations, and low toxicity to human cell lines. This combination of a defined bacterial target and low host toxicity is exactly why PrAMPs like oncocin are pursued as antibiotics with a mechanism different from conventional drugs.
Oncocin is one of the most engineered PrAMPs. Because its activity depends on both ribosome binding and uptake, researchers have made and tested large analog libraries to tune each step: substituting the arginines with homoarginine or D-arginine, replacing specific prolines with hydroxyproline or difluoroproline to adjust stability and hydrophobicity, truncating the sequence, and probing which residues contact the conserved ribosomal RNA. Some of these changes modestly improved potency against E. coli and Klebsiella while keeping toxicity negligible, and comparing a large set of Onc112 analogs showed that ribosome binding and bacterial uptake together — not either alone — govern antibacterial activity, a useful lesson for designing the next generation.
The peptide is also a building block for hybrid antibiotics. Fragments of oncocin have been conjugated to the macrolide antibiotic desmycosin, producing compounds that bind the ribosome and act against some macrolide-resistant bacteria, and oncocin-related decapeptides have been fused with membrane-depolarizing triphenylphosphonium groups to broaden their spectrum to Gram-positive bacteria while keeping selectivity for bacterial over human ribosomes. These are laboratory studies of a research antibiotic lead, not treatments given to people.
Through all of this, oncocin remains a research peptide. No published study has given it to people as a treatment, it is not approved anywhere, and material sold online under this name is an unregulated research chemical. Nothing here is a dose or a therapy; this page records what the published science says.
Mechanism of Action
Oncocin (lead Onc112) is a designed, proline- and arginine-rich antimicrobial peptide (a PrAMP) that is non-lytic: it diffuses across the Gram-negative outer membrane, is pumped in by the SbmA transporter, and binds the 70S ribosome exit tunnel to block protein synthesis (it also binds DnaK). Mainly Gram-negative, non-hemolytic; one of the most engineered PrAMP leads.
Designed insect-derived PrAMP
An optimized 19-residue proline/arginine-rich peptide (Onc112) engineered from insect PrAMPs (oncopeltus/pyrrhocoricin lineage) ~2010 (PMIDs 32840100, 34902208).
Uptake + ribosome block
Diffuses across the outer membrane, is imported by the SbmA transporter, and binds the 70S ribosome exit tunnel to inhibit protein synthesis; also binds DnaK (PMIDs 34902208, 41114226).
Gram-negative spectrum, low toxicity, engineering
Mainly Gram-negative with very low host toxicity (<1% hemolysis in analogs); heavily engineered (hydroxyproline/difluoroproline, D-Arg, antibiotic conjugates) (PMIDs 37797458, 36180983).
Published Research
These are studies of oncocin read from their PubMed records on November 7, 2026: a plasmid-expression characterization of oncocin binding the ribosome; truncated and disubstituted variants targeting the ribosome; structure-activity studies with guanidinylation, hydroxyproline and difluoroproline; a comparison of Onc112 analogs' ribosome binding and bacterial uptake; and hybrid conjugates with a macrolide antibiotic or a membrane-active group. The evidence is in bacteria and cell-free systems; oncocin has not been given to people as a treatment.
Truncated and disubstituted oncocin variants with improved activity
Using a cell-based expression system in E. coli, a shortened oncocin sequence was found to keep antibiotic activity, and cationic substitutions (P4K and L7R) improved potency versus the parent 19-mer; probing and modelling mapped the variants' contacts with conserved ribosomal RNA, giving a framework for structure-guided PrAMP design (an in-vitro study).
Triphenylphosphonium analogs of oncocin/bactenecin peptides
Conjugating a decapeptide related to bactenecin 7 and oncocin 112 with a triphenylphosphonium group raised its affinity for bacterial ribosomes and broadened its spectrum to Gram-positive bacteria (via membrane depolarization) while keeping it a more selective inhibitor of bacterial than human translation, and non-toxic to mammalian cells (an in-vitro study).
Structure-activity study of oncocin with modified residues
Replacing oncocin's arginines with homoarginine and its prolines with hydroxyproline or difluoroproline produced analogs that kept or slightly improved activity; the best, with three difluoroproline substitutions and stabilizing D-arginine changes, was potent against E. coli and Klebsiella with under one percent hemolysis and very low cell toxicity — a stability and potency optimization (an in-vitro study).
Oncocin-macrolide conjugates against resistant bacteria
Conjugates of N-terminal oncocin fragments with the macrolide antibiotic desmycosin bound the E. coli ribosome, inhibited bacterial protein synthesis and suppressed growth, and some were active against macrolide-resistant strains — a hybrid-antibiotic strategy characterized by molecular-dynamics modelling (an in-vitro study).
Ribosome binding and uptake govern Onc112 activity
Across 47 Onc112 analogs, neither ribosome-binding nor bacterial-uptake data alone predicted antibacterial potency; higher net positive charge tended to help, but activity reflected a complex interplay of membrane diffusion, transport, off-target binding and intracellular distribution — cautioning that in-vitro binding/uptake data are not sufficient for rational PrAMP design (an in-vitro study).
Expression and characterization of oncocin binding ribosomes
A plasmid-based system expressed oncocin inside E. coli and showed the internally produced peptide strongly inhibited bacterial growth; chemical footprinting confirmed its binding to the ribosomal RNA (consistent with external studies, plus extra contacts), and truncated/mutated versions revealed which residues matter for activity and for cellular transport (an in-vitro study).
No Established Human Dose
Oncocin is a designed research peptide; it has not been given to people as a treatment. The work is in bacteria and cell-free systems, almost always with synthetic analogs, at experimental amounts that do not carry over to people. No regulator has approved any dose, and no published human dose exists, so no amount is printed here.
What this rests on: PMID 34902208, PMID 37797458, PMID 41114226.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no label and no published test that says what forms or vial sizes Oncocin is sold in. A vial's own label is a seller's claim, not a source.
Mixing a vial: a worked example
Unknown: no human dose of Oncocin has been established (see No Established Human Dose below), so there is no amount to work out. The reconstitution calculator does the arithmetic for any vial, water and dose.
Storage before and after mixing
Unknown: no label or published stability study on file says how to store Oncocin, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Oncocin stays intact once mixed.
How it is taken
Unknown: with no established human dose, there is no established way of taking Oncocin. What the human studies gave and how is set out under No Established Human Dose.
What to expect, and when
How long it stays in the body: a half-life of not established for humans; a short linear peptide, analogs engineered for protease stability. After about five half-lives almost none is left.
When effects appear: unknown; no source on this page gives a time to effect for Oncocin. Results reported in the studies are under Published Research.
Source: half-life: PMID 37797458.
Side effects, and when to stop or get help
From the Side Effects section: No human adverse-event data exist: no published study has administered oncocin to people; Unlike membrane-disrupting peptides, oncocin is non-lytic and its analogs are routinely reported as non-hemolytic (under 1% at high doses) and low-toxicity to human cell lines (PMID 37797458) — research findings, not human data; Its spectrum is mainly Gram-negative and depends on bacterial uptake, so activity can be lost if the importing transporter changes (PMID 34902208); Material sold online as 'oncocin' is an unregulated research chemical of unverified content. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Oncocin. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“Oncocin is a research peptide that has not been given to people as a drug, so there is no human safety profile; the points below reflect that research status and its biology”).
Interactions
Unknown: a PubMed search for human interaction studies of Oncocin (reviewed 2026-11-07) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Oncocin products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: Research Chemical (Not a drug: Drugs@FDA and the openFDA label endpoint hold no record, and FDA GSRS and ChEMBL hold no approved-drug record for oncocin (searched November 7, 2026)). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
Oncocin is a research peptide that has not been given to people as a drug, so there is no human safety profile; the points below reflect that research status and its biology.
Contraindications & Cautions
Oncocin has no approved use and no label. These points reflect its research status.
Legal Status
Oncocin is a designed antimicrobial peptide used as a research compound; it is not a drug and is not approved in any country.
Frequently Asked Questions
?What is oncocin?
A designed, optimized proline- and arginine-rich antimicrobial peptide (a PrAMP), engineered around 2010 from insect defence peptides. Its lead form, Onc112, is 19 amino acids (VDKPPYLPRPRPPRRIYNR) (PMID 32840100).
?How does it work?
It is non-lytic: it crosses the Gram-negative outer membrane, is imported by a bacterial transporter (SbmA), and binds inside the ribosome to block protein synthesis (it also binds DnaK) — so it is gentle on host cells (PMID 34902208).
?How does it relate to apidaecin and drosocin?
All three are non-lytic, ribosome-targeting proline-rich antimicrobial peptides; apidaecin and drosocin are natural (honeybee and fruit fly), while oncocin is a designed, optimized analog of insect PrAMPs (PMIDs 34902208, 41114226).
?Is it approved or available to buy?
No. Oncocin is not a medicine, has no FDA application or label, and is approved nowhere. Material sold online as oncocin is an unregulated research chemical. Grey Peptides lists no sellers and recommends no source; this page records the published science.
References
- [mechanism] Wolak T, et al. "Truncated and Disubstituted (P4K and L7R) Oncocin Peptides Target the Ribosome with Improved Antibacterial Activity." ACS Omega, 2025;10(40):47493-47503. PMID: 41114226.
- [mechanism] Tereshchenkov AG, et al. "Triphenylphosphonium Analogs of Short Peptide Related to Bactenecin 7 and Oncocin 112 as Antimicrobial Agents." Pharmaceutics, 2024;16(1). PMID: 38276518.
- [mechanism] Shaikh AY, et al. "Structure-activity study of oncocin: On-resin guanidinylation and incorporation of homoarginine, 4-hydroxyproline or 4,4-difluoroproline residues." Bioorg Chem, 2023;141:106876. PMID: 37797458.
- [mechanism] Khairullina ZZ, et al. "Conjugates of Desmycosin with Fragments of Antimicrobial Peptide Oncocin: Synthesis, Antibacterial Activity, Interaction with Ribosome." Biochemistry (Mosc), 2022;87(9):871-889. PMID: 36180983.
- [mechanism] Kolano L, et al. "Effect of Amino Acid Substitutions on 70S Ribosomal Binding, Cellular Uptake, and Antimicrobial Activity of Oncocin Onc112." Chembiochem, 2022;23(5):e202100609. PMID: 34902208.
- [mechanism] Muthunayake NS, et al. "Expression and In Vivo Characterization of the Antimicrobial Peptide Oncocin and Variants Binding to Ribosomes." Biochemistry, 2020;59(36):3380-3391. PMID: 32840100.
- [other] Oncocin (and its lead analog Onc112) is a designed, optimized proline- and arginine-rich antimicrobial peptide developed from insect proline-rich antimicrobial peptides (the oncopeltus/pyrrhocoricin lineage) by Knappe, Hoffmann and colleagues around 2010 as an antibacterial lead against Gram-negative pathogens. Its structure, mechanism and many analogs are described in the studies carded on this page (read November 7, 2026).
- [other] US FDA, Drugs@FDA and the openFDA label endpoint, searched November 7, 2026: no application and no label record for oncocin. It is a designed research antimicrobial peptide, not a drug; FDA GSRS and ChEMBL hold no approved-drug record for it.
Sources & Citations
The six studies carded above were read from their PubMed records on November 7, 2026. Oncocin's design from insect proline-rich antimicrobial peptides, its Onc112 lead sequence, its non-lytic mechanism (outer-membrane diffusion, SbmA-mediated uptake, binding the 70S ribosome exit tunnel, and DnaK), its mainly Gram-negative spectrum and low host toxicity, and its many engineered analogs and antibiotic conjugates are from the studies carded here; the design is the ~2010 work of Knappe, Hoffmann and colleagues. The absence of US approval or a drug record from Drugs@FDA, openFDA, FDA GSRS and ChEMBL was checked the same day. Grey Peptides sells nothing and links to no vendor.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.